Fecal transplant plus cancer immunotherapy for lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial studies whether giving a fecal microbiota transplant (a stool-based sample from a carefully screened donor) alongside immune checkpoint inhibitors can improve outcomes in people with lung cancer. It aims to change the gut bacteria to help the immune system work better against the cancer.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Be an adult (18+) with a confirmed cancer diagnosis, specifically planning lung cancer treatment.
- You plan to start chemotherapy and/or immune checkpoint inhibitors and/or targeted therapy.
- Your current health status should be fairly good (ECOG 0 to 2).
- Do not have a serious allergy, or any allergy that would be a problem with omeprazole (a common stomach medicine used in studies).
- Do not take probiotics or other pre-/probiotics in the 4 weeks before enrollment.
- You must be able to safely swallow the study capsules and not be pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether a fecal microbiota transplant (FMT) — transferring healthy bacteria from a donor's stool into your gut — combined with the immunotherapy drug tislelizumab can help treat advanced non-small cell lung cancer (NSCLC) that has progressed after prior treatments. It aims to see if this combination can improve outcomes by boosting your immune system's response.
This trial tests whether giving patients a fecal microbiota transplant (healthy bacteria from stool of patients who responded to immunotherapy) before standard immunotherapy is safe and feasible for stage II-III lung cancer. It may improve how well the immune system fights cancer.
This trial tests whether taking an oral fecal transplant (MaaT033) along with the immunotherapy drug cemiplimab can help people whose lung cancer stopped responding after antibiotics. It's for people with advanced non-small cell lung cancer whose cancer got worse after standard immunotherapy.
This trial tests a combination of fecal microbiota transplant (FMT), chemotherapy (SOX), and an immunotherapy drug (Sintilimab) as a first treatment for advanced stomach or gastroesophageal junction cancer that cannot be removed by surgery. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial studies whether changes in gut bacteria can help predict how well immunotherapy works for solid cancers. It also tests whether stool (fecal microbiota) from certain immunotherapy-responding people can improve outcomes for others who are not responding well.
This early-phase study tests whether changing your gut bacteria with a fecal transplant can improve diarrhea or colitis caused by cancer immunotherapy. It may help people whose symptoms have not fully settled with standard treatments like steroids and other immune-blocking medicines.
Hear when a new Metastatic Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.